格隆汇2月24日丨哈三联(002900.SZ)公布，全资子公司兰西哈三联制药有限公司（简称"兰西制药"）于 2026年2月13日收到政府补助600万元，占公司最近一期经审计归属于上市公司股东净利润的比例为 10.23%。该笔补助系与收益相关的政府补助。截至本公告披露日，兰西制药已实际收到前述补助款 项。 ...

1月16日，国发股份发布2025年度业绩预告称，预计全年实现营业收入约3.3亿元，扣除无关收入后仍为 3.3亿元；预计归母净亏损约8500万元，同比减亏900万元，减亏幅度10%；扣非归母净亏损约8550万 元，同比减亏450万元。业绩预亏主要受子公司高盛生物盈利转亏、制药板块营收下滑及商誉减值计提 影响。 2月24日，国发股份（600538.SH）发布公告，针对上海证券交易所关于公司2025年度业绩预告的问询 函作出详细回复，就营业收入合规性、医药流通增速合理性及商誉减值等核心问题逐一说明。公司明确 营收扣除符合监管规定，医药流通增长具备业务支撑，同时披露拟对全资子公司广州高盛生物计提约 6200万元商誉减值。 上交所对公司医药流通业务增速高于行业水平提出质疑，要求详细说明增长合理性。国发股份从业务结 构、物流模式、区域市场、季度分布四方面进行了回应。 国发股份表示，公司医药流通收入以医院销售为主，占比达86%，快批、零售等板块有所下滑；物流以 自有仓库与配送体系为主，仅单一医院医疗器械合作使用第三方仓储，收入确认政策未发生变更，以客 户签收或实际使用为依据。 从区域来看，公司核心市场北部湾三市药品市场增速 ...

Market Overview - On the first trading day after the resumption of Northbound trading, Hong Kong's three major indices collectively declined, with the Hang Seng Index falling below the 27,000 mark, closing down 1.82% or 491.59 points at 26,590.32 points, with a total turnover of HKD 250.99 billion [1] - The Hang Seng China Enterprises Index dropped 2.06% to 9,007.86 points, while the Hang Seng Tech Index fell 2.13% to 5,270.70 points [1] Sector Performance - The technology sector remains a long-term investment focus, with valuation pressure easing after recent pullbacks, and potential for rebound driven by accelerated AI model updates and applications [1] - The energy and precious metals sectors are expected to rise amid heightened geopolitical risks in the Middle East and adjustments in U.S. tariff policies [1] - The consumer sector, currently undervalued, is anticipated to have upward potential as consumption policies are strengthened [1] Blue-Chip Stocks - WH Group (00288) led blue-chip gains, rising 4.42% to HKD 10.39, contributing 5.87 points to the Hang Seng Index [2] - Other notable blue-chip performers included Henderson Land (00012) up 2.08% and China Resources Beer (00291) up 2.02% [2] - China Biologic Products (01177) fell 6.58%, negatively impacting the index by 7.48 points [2] Hot Sectors - Major tech stocks faced pressure, with Tencent down over 3% and Alibaba down over 2% [3] - Storage concepts saw significant gains, with Zhaoyi Innovation (03986) up 11.91% and Longsys Technology (06809) up 4.92% [3] - Oil and gas stocks rose amid concerns over escalating tensions in Iran, with Shandong Molong (00568) up 11.41% [4] AI and Technology - The AI sector continues to show promise, with significant growth in token usage, particularly in Chinese models, which account for 61% of the total token volume [5] - The market anticipates ongoing rapid growth in AI applications and commercial viability [5] Film Sector - The film sector faced challenges, with the 2026 Spring Festival box office down approximately 40% year-on-year, indicating a need for improved content quality [6] - Major film stocks like Maoyan Entertainment (01896) and Huayi Brothers (01003) saw declines of 8.18% and 5.26%, respectively [6] Notable Stock Movements - Kwan Hung Holdings (01888) surged 12.37% following a profit forecast indicating a 165% increase in net profit for the fiscal year ending December 2025 [7] - Weichai Power (02338) rose 7.29% after a report highlighted its emergency generator's use in a major data center [8] - China Shipbuilding Defense (00317) reached a new high, up 5.37%, following a significant shipbuilding contract announcement [9] - Standard Chartered (02888) saw a 3.07% increase after reporting a 6% rise in operating income for the fiscal year 2025 [10] - China Duty Free Group (01880) faced a 10.51% drop due to losing some operating rights at major airports [11]

格隆汇2月24日丨哈三联(002900.SZ)公布，全资子公司兰西哈三联制药有限公司（简称"兰西制药"）于 2026年2月13日收到政府补助600万元，占公司最近一期经审计归属于上市公司股东净利润的比例为 10.23%。该笔补助系与收益相关的政府补助。截至本公告披露日，兰西制药已实际收到前述补助款 项。 ...

七年春节坚守，智能制造助力医药保供加速 除夕夜，在辽宁方大集团东北制药细河原料药厂区202分厂外包装操作室内，伴随着机器轰鸣声，一箱 箱盐酸小檗碱有序完成包装。 "设备专人负责、实时巡检、记录留痕，每一道工序都不能马虎。"林艳一边紧盯设备参数，一边向贝壳 财经记者介绍，"我们优化了包装节奏，减少工序等待，1月份已经超额完成产量计划，就是要全力以赴 冲刺一季度'开门红'，保障市场供应不脱节。" 进入东北制药28年，今年已是林艳第七次在岗位上度过春节。 春节前的排班，从来不是一件简单的事。但在林艳眼里，这份"难题"却总能在默契中化解。 "外地的员工，家远的，优先让他们先回，别耽误了团圆。"这是每年排班时不成文的规矩。车间里，离 家近的、本地的同事会主动往前站，等外地同事返岗后，大家再轮换着休息。 春节期间，东北制药202分厂盐酸小檗碱后部工段的灯火依旧通明。工段长林艳又一次出现在春节值班 表里，这已经是她连续第七年在岗位上度过春节假期。 作为医药生产线上的一名"老兵"，林艳深知自己手中生产的原料药产品，都可能是下游药企和患者节日 里的急需。而在医药企业的生产厂区和药房门店内，像林艳这样坚守岗位的员工随处可见：十多 ...

Core Viewpoint - Federal Pharmaceutical's UBT251 injection has successfully completed Phase II clinical trials for overweight/obese patients in China, demonstrating significant weight loss and safety [1][2] Group 1: Clinical Study Details - The Phase II clinical study involved 205 participants with a baseline average weight of 92.2 kg and a BMI of 33.1 kg/m2 [1] - Participants were randomly assigned to receive UBT251 at doses of 2mg, 4mg, or 6mg, or a placebo, with weekly subcutaneous injections for 24 weeks [1] Group 2: Study Results - After 24 weeks, the UBT251 treatment groups achieved an average weight reduction of up to -19.7% (-17.5 kg), compared to -2.0% (-1.6 kg) in the placebo group [2] - Improvements in key secondary endpoints such as waist circumference, blood sugar, blood pressure, and blood lipids were significantly better in the UBT251 groups compared to the placebo [2] Group 3: Safety and Next Steps - UBT251 demonstrated good overall safety and tolerability, with no withdrawals due to adverse events, which were primarily mild to moderate gastrointestinal reactions [2] - The successful Phase II results support the initiation of Phase III clinical trials for overweight/obese patients in China [2]

Core Viewpoint - The clinical study of UBT251 injection, developed by the company's subsidiary, has successfully completed Phase II trials in overweight/obese patients in China, demonstrating significant weight loss and safety [1][2]. Group 1: Clinical Study Design and Results - The Phase II clinical study involved 205 participants with a baseline average weight of 92.2 kg and a BMI of 33.1 kg/m², using a randomized, double-blind, placebo-controlled design [1]. - Participants were assigned to receive either UBT251 injection at doses of 2mg, 4mg, or 6mg, or a placebo, with weekly subcutaneous injections for 24 weeks [1]. - The primary endpoint was the percentage change in weight from baseline after 24 weeks of treatment [1]. Group 2: Efficacy and Safety Outcomes - Results showed that the UBT251 treatment groups achieved a maximum average weight reduction of -19.7% (-17.5 kg), compared to -2.0% (-1.6 kg) in the placebo group [2]. - Key secondary endpoints, including waist circumference, blood sugar, blood pressure, and blood lipids, showed significant improvement in the UBT251 groups compared to placebo [2]. - The overall safety and tolerability of UBT251 were good, with no withdrawals due to adverse events, which were primarily gastrointestinal and mostly mild to moderate in severity [2].

格隆汇2月24日丨上海医药(02607.HK)公布，近日，公司下属常州制药厂有限公司(以下简称"常州制药 厂")生产的利伐沙班片(以下简称"该药品")收到新加坡食品药品监督管理局(HSA)颁发的药品注册证书， 该药品获得批准上市。 2025 年 5 月，常州制药厂的利伐沙班片获得美国食品药品监督管理局批准文号，并于 2025 年 10 月获 得马来西亚药品注册证书。截至本公告日，公司针对该药品在东南亚市场(即泰国、新加坡、马来西亚 及菲律宾)上市另投入的研发费用约人民币 324.82 万元。 利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险；用于治疗和预防深静脉血栓形成 (DVT)；用于治疗肺栓塞(PE)；用于预防急性病患者静脉血栓栓塞(VTE)等。利伐沙班片最早由 BAYER 和 JANSSEN 联合研发并于 2011 年在美国上市。 ...

同仁堂制药厂产品儿感清口服液、锁阳固精丸、人参健脾丸、大黄䗪虫丸取得加拿大卫生部颁发的《产 品许可证(三类)》系产品上市许可。上述产品若拟在加拿大销售，后续还需根据加拿大卫生部法规要 求，完成包括但不限于对生产场地的加拿大生产质量体系认证等行政审批事项，该等审批可能存在一定 不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 智通财经APP讯，同仁堂(600085.SH)发布公告，公司分支机构北京同仁堂股份有限公司同仁堂制药厂 (以下简称同仁堂制药厂)收到加拿大卫生部核准签发的《产品许可证(三类)》，同仁堂制药厂产品儿感 清口服液、锁阳固精丸、人参健脾丸、大黄䗪虫丸获得加拿大产品注册。 ...

Core Viewpoint - The company has successfully completed Phase II clinical trials for its innovative drug UBT251 injection in overweight/obese patients in China, demonstrating significant weight loss and safety profile [1][2]. Group 1: Clinical Trial Details - The Phase II clinical study involved 205 participants with obesity (BMI ≥ 28.0 kg/m²) or overweight patients with at least one weight-related comorbidity (24.0 kg/m² ≤ BMI < 28.0 kg/m²) [1]. - Participants were randomly assigned in a 1:1:1:1 ratio to receive UBT251 injection at doses of 2 mg, 4 mg, or 6 mg, or a placebo, administered once weekly for 24 weeks [1]. - The primary endpoint was the percentage change in weight from baseline after 24 weeks of treatment [1]. Group 2: Results and Efficacy - After 24 weeks, the UBT251 treatment groups achieved a maximum average weight reduction of -19.7% (-17.5 kg), compared to -2.0% (-1.6 kg) in the placebo group [2]. - Significant improvements were also observed in secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids, all showing better results than the placebo [2]. Group 3: Safety and Next Steps - The overall safety and tolerability of UBT251 were good, with no participants dropping out due to adverse events, which were similar to those of comparable drugs and mostly mild to moderate gastrointestinal reactions [2]. - The successful Phase II results support the progression to Phase III clinical trials for UBT251 in overweight/obese patients in China [2].